Aptinyx has concluded the enrolment of subjects in the ongoing Phase IIb clinical trial of its new oral therapy, NYX-2925, to treat painful diabetic peripheral neuropathy (DPN).

A new N-methyl-D-aspartate (NMDA) receptor positive allosteric modulator, NYX-2925 is presently being analysed in a Phase II trial to treat chronic pain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The randomised, placebo-controlled, double-blind Phase IIb trial will analyse the efficacy and safety of NYX-2925 in subjects with advanced painful DPN.

After the screening period, qualified subjects will be categorised to receive once-daily doses of either 50mg NYX-2925 or placebo during the treatment duration.

The change from baseline in weekly average daily pain score over a duration of 12 weeks as assessed on the ten-point numeric rating scale will be the primary goal of the trial.

In the trial, several secondary and exploratory goals linked to pain and the quality of life of the subject will also be analysed.

Subjects who complete the 12-week treatment duration will be subsequently followed up for safety after 30 days.

Aptinyx anticipates reporting data from the trial in the early-to-mid-second quarter of next year.

Aptinyx CEO Norbert Riedel said: “We look forward to completing the study and reporting results next year, which, if positive, would support the late-stage clinical development of NYX-2925 in painful DPN.

“This readout will be the first of the multiple Phase II data catalysts we expect across our development pipeline over the next 24 months.”

A neuropathic pain condition, painful DPN affects nearly 7.5 million individuals in the US.

It develops in 60%-70% of diabetes patients when chronically increased levels of glucose injure nerves and disrupt information transmission between the central nervous system and other body parts.

Earlier this year, Aptinyx restarted recruiting and screening participants in a Phase II trial of NYX-2925 to treat painful DPN patients.